Consistently, genetic variants in cardiomyopathy-causative genes, such as truncation variants in the titin gene, significantly increased the risk of anthracycline drug-associated cardiomyopathy and adverse cardiac events [5, 6]. This evidence concerns the gene TTN and cardiomyopathy.